EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

OPTIMIZATION OF THE CLINICAL JOURNEY OF UNFIT PATIENTS WITH NEWLY DIAGNOSED IDH1M ACUTE MYELOID LEUKEMIA

Adriano Venditti, Marta Riva, Livio Pagano, Giovanni Marconi, Nicola Fracchiolla, Romano Danesi, Antonio Curti, Anna Candoni, Erika Borlenghi, Maria Teresa Voso

Mediterranean Journal of Hematology and Infectious Diseases · 31.10.2026 · 18 (1) · e2026086

DOI: 10.4084/mjhid.2026.086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mediterranean Journal of Hematology and Infectious Diseases, online erschienen am 31.10.2026. Verfasst von Adriano Venditti und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of acute myeloid leukemia (AML) in elderly or unfit patients has undergone a paradigm shift with the integration of molecular diagnostics and targeted therapies. Among actionable alterations, IDH1 mutations define a biologically distinct subgroup for which ivosidenib combined with azacitidine has recently emerged as a standard of care. However, initial clinical management remains complex. Three main themes emerged from the expert panel’s discussion: all patients should be tested for IDH1m, with turnaround time of 3-5 days; adequate patient monitoring during treatment is essential to detect the earliest signs of differentiation syndrome and QTc prolongation; appropriate management of concomitant therapies is required, not only for azole derivatives administered for antifungal prophylaxis, where need. This paper provides a comprehensive and evidence-based framework for optimizing early management in unfit patients with newly diagnosed IDH1-mutated AML, integrating data from randomized trials, real-world studies, and updated evidence on antifungal prophylaxis and drug–drug interactions in the era of targeted therapies.

Zitieren

APA

Venditti, A., Riva, M., Pagano, L., Marconi, G., Fracchiolla, N., Danesi, R., Curti, A., Candoni, A., Borlenghi, E., & Voso, M. T. (2026). OPTIMIZATION OF THE CLINICAL JOURNEY OF UNFIT PATIENTS WITH NEWLY DIAGNOSED IDH1M ACUTE MYELOID LEUKEMIA. Mediterranean Journal of Hematology and Infectious Diseases, 18(1), e2026086. https://doi.org/10.4084/mjhid.2026.086

Vancouver

Venditti A, Riva M, Pagano L, Marconi G, Fracchiolla N, Danesi R, et al. OPTIMIZATION OF THE CLINICAL JOURNEY OF UNFIT PATIENTS WITH NEWLY DIAGNOSED IDH1M ACUTE MYELOID LEUKEMIA. Mediterranean Journal of Hematology and Infectious Diseases. 2026;18(1):e2026086. doi:10.4084/mjhid.2026.086

BibTeX
@article{Venditti2026,
  author = {Venditti, Adriano and Riva, Marta and Pagano, Livio and Marconi, Giovanni and Fracchiolla, Nicola and Danesi, Romano and Curti, Antonio and Candoni, Anna and Borlenghi, Erika and Voso, Maria Teresa},
  title = {OPTIMIZATION OF THE CLINICAL JOURNEY OF UNFIT PATIENTS WITH NEWLY DIAGNOSED IDH1M ACUTE MYELOID LEUKEMIA},
  journal = {Mediterranean Journal of Hematology and Infectious Diseases},
  year = {2026},
  volume = {18},
  number = {1},
  pages = {e2026086},
  doi = {10.4084/mjhid.2026.086}
}
Kostenlos starten →